162 related articles for article (PubMed ID: 38139260)
1. The LIFR Inhibitor EC359 Effectively Targets Type II Endometrial Cancer by Blocking LIF/LIFR Oncogenic Signaling.
Spencer N; Rodriguez Sanchez AL; Gopalam R; Subbarayalu P; Medina DM; Yang X; Ramirez P; Randolph L; Aller EJ; Santhamma B; Rao MK; Tekmal RR; Nair HB; Kost ER; Vadlamudi RK; Viswanadhapalli S
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139260
[TBL] [Abstract][Full Text] [Related]
2. EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer.
Viswanadhapalli S; Luo Y; Sareddy GR; Santhamma B; Zhou M; Li M; Ma S; Sonavane R; Pratap UP; Altwegg KA; Li X; Chang A; Chávez-Riveros A; Dileep KV; Zhang KYJ; Pan X; Murali R; Bajda M; Raj GV; Brenner AJ; Manthati V; Rao MK; Tekmal RR; Nair HB; Nickisch KJ; Vadlamudi RK
Mol Cancer Ther; 2019 Aug; 18(8):1341-1354. PubMed ID: 31142661
[TBL] [Abstract][Full Text] [Related]
3. LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer.
Tang W; Ramasamy K; Pillai SMA; Santhamma B; Konda S; Pitta Venkata P; Blankenship L; Liu J; Liu Z; Altwegg KA; Ebrahimi B; Pratap UP; Li X; Valente PT; Kost E; Sareddy GR; Vadlamudi RK; Nair HB; Tekmal RR; Viswanadhapalli S
Cell Death Discov; 2021 Aug; 7(1):216. PubMed ID: 34400617
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of LIFR Blocks Adiposity-Driven Endometrioid Endometrial Cancer Growth.
Blankenship L; Pratap UP; Yang X; Liu Z; Altwegg KA; Santhamma B; Ramasamy K; Konda S; Chen Y; Lai Z; Zheng S; Sareddy GR; Valente PT; Kost ER; Nair HB; Tekmal RR; Vadlamudi RK; Viswanadhapalli S
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358818
[TBL] [Abstract][Full Text] [Related]
5. Targeting LIF/LIFR signaling in cancer.
Viswanadhapalli S; Dileep KV; Zhang KYJ; Nair HB; Vadlamudi RK
Genes Dis; 2022 Jul; 9(4):973-980. PubMed ID: 35685476
[TBL] [Abstract][Full Text] [Related]
6. The Pleiotropic role, functions and targeted therapies of LIF/LIFR axis in cancer: Old spectacles with new insights.
Halder S; Parte S; Kshirsagar P; Muniyan S; Nair HB; Batra SK; Seshacharyulu P
Biochim Biophys Acta Rev Cancer; 2022 Jul; 1877(4):188737. PubMed ID: 35680099
[TBL] [Abstract][Full Text] [Related]
7. Leukemia inhibitory factor promotes gastric cancer cell proliferation, migration, and invasion via the LIFR-Hippo-YAP pathway.
Bian SB; Yang Y; Liang WQ; Zhang KC; Chen L; Zhang ZT
Ann N Y Acad Sci; 2021 Jan; 1484(1):74-89. PubMed ID: 32827446
[TBL] [Abstract][Full Text] [Related]
8. Decreased Endometrial Expression of Leukemia Inhibitory Factor Receptor Disrupts the STAT3 Signaling in Adenomyosis During the Implantation Window.
Yen CF; Liao SK; Huang SJ; Tabak S; Arcuri F; Lee CL; Arici A; Petraglia F; Wang HS; Kayisli UA
Reprod Sci; 2017 Aug; 24(8):1176-1186. PubMed ID: 27903796
[TBL] [Abstract][Full Text] [Related]
9. Next-Generation Sequencing Analysis of Gastric Cancer Identifies the Leukemia Inhibitory Factor Receptor as a Driving Factor in Gastric Cancer Progression and as a Predictor of Poor Prognosis.
Di Giorgio C; Marchianò S; Marino E; Biagioli M; Roselli R; Bordoni M; Bellini R; Urbani G; Zampella A; Distrutti E; Donini A; Graziosi L; Fiorucci S
Front Oncol; 2022; 12():939969. PubMed ID: 35847866
[TBL] [Abstract][Full Text] [Related]
10. Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation.
Morton SD; Cadamuro M; Brivio S; Vismara M; Stecca T; Massani M; Bassi N; Furlanetto A; Joplin RE; Floreani A; Fabris L; Strazzabosco M
Oncotarget; 2015 Sep; 6(28):26052-64. PubMed ID: 26296968
[TBL] [Abstract][Full Text] [Related]
11. Lidocaine Suppresses Gastric Cancer Development Through Circ_ANO5/miR-21-5p/LIFR Axis.
Guan E; Liu H; Xu N
Dig Dis Sci; 2022 Jun; 67(6):2244-2256. PubMed ID: 34050852
[TBL] [Abstract][Full Text] [Related]
12. Novel Long Non-coding RNA lncAMPC Promotes Metastasis and Immunosuppression in Prostate Cancer by Stimulating LIF/LIFR Expression.
Zhang W; Shi X; Chen R; Zhu Y; Peng S; Chang Y; Nian X; Xiao G; Fang Z; Li Y; Cao Z; Zhao L; Liu G; Sun Y; Ren S
Mol Ther; 2020 Nov; 28(11):2473-2487. PubMed ID: 32592689
[TBL] [Abstract][Full Text] [Related]
13. Expression of leukemia inhibitory factor and its receptor in breast cancer: a potential autocrine and paracrine growth regulatory mechanism.
Dhingra K; Sahin A; Emami K; Hortobagyi GN; Estrov Z
Breast Cancer Res Treat; 1998 Mar; 48(2):165-74. PubMed ID: 9596488
[TBL] [Abstract][Full Text] [Related]
14. High LIFr expression stimulates melanoma cell migration and is associated with unfavorable prognosis in melanoma.
Guo H; Cheng Y; Martinka M; McElwee K
Oncotarget; 2015 Sep; 6(28):25484-98. PubMed ID: 26329521
[TBL] [Abstract][Full Text] [Related]
15. Effects of leukemia inhibitory factor receptor on the adipogenic differentiation of human bone marrow mesenchymal stem cells.
Wang T; Yan R; Xu X; Yu H; Wu J; Yang Y; Li W
Mol Med Rep; 2019 Jun; 19(6):4719-4726. PubMed ID: 31059010
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the leukemia inhibitory factor receptor (LIFR) gene and Lifr deficiency cause urinary tract malformations.
Kosfeld A; Brand F; Weiss AC; Kreuzer M; Goerk M; Martens H; Schubert S; Schäfer AK; Riehmer V; Hennies I; Bräsen JH; Pape L; Amann K; Krogvold L; Bjerre A; Daniel C; Kispert A; Haffner D; Weber RG
Hum Mol Genet; 2017 May; 26(9):1716-1731. PubMed ID: 28334964
[TBL] [Abstract][Full Text] [Related]
17. PCBP1 regulates LIFR through FAM3C to maintain breast cancer stem cell self-renewal and invasiveness.
Streitfeld WS; Dalton AC; Howley BV; Howe PH
Cancer Biol Ther; 2023 Dec; 24(1):2271638. PubMed ID: 37927213
[TBL] [Abstract][Full Text] [Related]
18. The AB loop and D-helix in binding site III of human Oncostatin M (OSM) are required for OSM receptor activation.
Adrian-Segarra JM; Schindler N; Gajawada P; Lörchner H; Braun T; Pöling J
J Biol Chem; 2018 May; 293(18):7017-7029. PubMed ID: 29511087
[TBL] [Abstract][Full Text] [Related]
19. Regulation of neurokine receptor signaling and trafficking.
Nathanson NM
Neurochem Int; 2012 Nov; 61(6):874-8. PubMed ID: 22306348
[TBL] [Abstract][Full Text] [Related]
20. Utilizing cell line-derived organoids to evaluate the efficacy of a novel LIFR-inhibitor, EC359 in targeting pancreatic tumor stroma.
Hall BR; Cannon A; Thompson C; Santhamma B; Chavez-Riveros A; Bhatia R; Nair HB; Nickisch K; Batra SK; Kumar S
Genes Cancer; 2019 Feb; 10(1-2):1-10. PubMed ID: 30899415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
